Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Drug class

Government launches consultation on reclassification of gabapentinoids

The government has launched its consultation on the reclassification of pregabalin and gabapentin.

It follows a recommendation last year by the Advisory Council on the Misuse of Drugs that the drugs be reclassified as class C drugs because of the risks of “illegal diversion and medicinal misuse”.

A steep increase in the number of deaths linked to gabapentinoids, which are used for treating neuropathic pain, seizures and anxiety, prompted the decision.

Prior to 2009, there was less than one death per year attributed to the drugs, but in 2015 there were 137, the majority of which were associated with opioid use.

According to the data published in the journal Addiction earlier this year, the number of pregabalin and gabapentin prescriptions also increased from 1 million in 2004 to 10.5 million in 2015.

Gabapentinoids are increasingly being used illicitly to enhance the effects of heroin.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20204014

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Gabapentin

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.